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Abstract
Background: We demonstrated that mouse embryonic stem (ES) cells-derived vascular endothelial growth factor receptor-2
(VEGF-R2) positive cells could differentiate into both endothelial cells (EC) and mural cells (MC), and termed them as vascular
progenitor cells (VPC). Recently, we have established a method to expand monkey and human ES cells-derived VPC with the
proper differentiation stage in a large quantity. Here we investigated the therapeutic potential of human VPC-derived EC
and MC for vascular regeneration.
Methods and Results: After the expansion of human VPC-derived vascular cells, we transplanted these cells to nude mice
with hindlimb ischemia. The blood flow recovery and capillary density in ischemic hindlimbs were significantly improved in
human VPC-derived EC-transplanted mice, compared to human peripheral and umbilical cord blood-derived endothelial
progenitor cells (pEPC and uEPC) transplanted mice. The combined transplantation of human VPC-derived EC and MC
synergistically improved blood flow of ischemic hindlimbs remarkably, compared to the single cell transplantations.
Transplanted VPC-derived vascular cells were effectively incorporated into host circulating vessels as EC and MC to maintain
long-term vascular integrity.
Conclusions: Our findings suggest that the combined transplantation of human ES cells-derived EC and MC can be used as
a new promising strategy for therapeutic vascular regeneration in patients with tissue ischemia.
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Introduction
Embryonic stem (ES) cells, with their extensive regeneration
potential and functional multilineage differentiation capacity, are
now highlighted as promising cell sources for regenerative
medicine. Previously we reported that mouse ES cells-derived
vascular endothelial growth factor receptor-2 (VEGFR2) positive
cells could differentiate into both endothelial cells (EC) and mural
cells (MC) (pericytes and vascular smooth muscle cells) and
reproduce the vascular organization process, which we termed
‘‘vascular progenitor cells (VPC)’’ [1]. Transplanted VPC into
tumor-bearing nude mice were incorporated into blood vessels and
significantly increased blood flow, which suggests that VPC might
be useful for augmenting vessel growth in ischemic tissue [2].
We have demonstrated that human as well as monkey ES cells
possessed different differentiation kinetics of VPC derived from
mouse ES cells [3,4]. In contrast to mouse ES cells, undifferen-
tiated human ES cells already expressed VEGFR2. After the
induction of differentiation on OP9 feeder cells, VEGFR2 positive
and tumor rejection antigen-1 (TRA1: a marker indicative of
undifferentiated cell phenotype) negative cells appeared at day 8.
We confirmed that VEGFR2 positive cells at this stage effectively
differentiated into both VE-cadherin positive EC and a-smooth
muscle actin (aSMA) positive MC to suffice as human VPC.
PLoS ONE | www.plosone.org 1 February 2008 | Volume 3 | Issue 2 | e1666Human VPC-derived VEGFR2
+ VE-cadherin
+ cells, which were
considered as EC at an early differentiation stage, formed a
network structure on Matrigel-coated dishes.
Based upon these works, in the present study we transplanted
human VPC-derived vascular cells; that is, EC and MC in a
murine hindlimb ischemia model. By transplantation of these EC
and MC differentiated from human VPC, we investigated whether
and how they could be incorporated as EC and MC into the sites
of neovascularization, compared to human peripheral blood and
umbilical cord blood-derived endothelial progenitor cell (EPC)
transplantation [5–7]. Furthermore, we specifically asked whether
the combined transplantation of human VPC-derived EC and MC
could induce stable vascular regeneration to achieve long-term
vascular integrity.
Results
Characterization of Transplanted Human VPC-derived
Vascular Cells
Flow cytometric analysis disclosed that 20–40% of expanded
human VPC-derived EC retained the expression of the endothelial
cell-related markers, including VE-cadherin, VEGFR2, CD34,
CD31 and CD105, and all of the cells were negative for a
panleukocyte marker CD45, monocyte/macrophage marker
(CD11b), and stem/progenitor makers (AC133 and c-kit)
(Figure 1a). By the double immunostaining of CD31 and aSMA,
the cells negative for CD31 were exclusively positive for aSMA
(Figure 1b), but weak or negative for staining with other MC
markers, including calponin, smooth muscle myosin heavy chain 1
(SM1) and 2 (SM2) (data not shown).
Immunocytochemistry of expanded human VPC-derived MC
revealed that all these cells were positive for aSMA, calponin, SM1
and SM2 (Figure 1c). Analysis by reverse transcription-polymerase
chain reaction (RT-PCR) also confirmed that mRNA expressions
of these MC markers were upregulated in human VPC-derived
MC and negative in sorted VE-cadherin
+ fraction of expanded
human VPC-derived EC (Figure 1d). Although cultured human
aortic smooth muscle cells (hAoSMC) expressed a high level of h-
caldesmon, its expression in human VPC-derived MC was not
detected. Furthermore, mRNA for skeletal (myogenin and MyoD)
or cardiac (cardiac troponin T (cTnT) and I (cTnI)) specific
marker was not detected in human VPC-derived MC (Figure 1e).
Characterization of Transplanted Human EPC
Flow cytometric analysis of pEPC demonstrated that these cells
mainly exhibited two light-scattering properties: one was consis-
tent with a relatively large cell size (gate P1) and the other was
found in a smaller gate P2 (Figure 2a). The P1-gated cells were
positive for DiI-acLDL uptake and ulex-lectin binding (Figure 2b),
and exhibited the reported EPC phenotype [6,8]. However, the
smaller P2-gated cells were low positive for DiI-acLDL/ulex-lectin
(Figure 2c). Therefore, we performed subsequent fluorescence
activated cell sorter (FACS) analysis of pEPC on the P1-gated cells.
As shown in Figure 2d, nearly all pEPC expressed the
hematopoietic markers CD45 (99.9%) and CD54 (99.9%) and the
monocyte/macrophage markers CD14 (99.0%), CD11b (98.7%),
and CD11c (98.9%). The monocyte/macrophage or endothelial
markers CD31 (58.3%) and CD105 (70.1%) were also expressed. A
much lower percentage of these cells expressed the endothelial cell-
related markers VE-cadherin (1.6%), VEGFR2 (5.4%), and von
Willebrand Factor (vWF) (0.3%), or the stem/progenitor cell
markers AC133 (1.0%), c-kit (0.4%), and CD34 (0.2%).
Flow cytometric analysis of magnetic cell separation system
(MACS)-sorted uEPC showed more than 80% of these cells were
positive for CD34 (data not shown). Similar to pEPC, almost all
CD34
+ fraction of uEPC expressed the hematopoietic markers
CD45 (99.0%) and CD54 (84.9%) (Figure 2e). However, the
expression of monocyte/macrophage markers was limited in uEPC
(CD14 5.7%, CD11b 99.7%, CD11c 21.3%), and significant
number of these cells was positive for the endothelial cell-related
markers, including VE-cadherin (11.2%), VEGFR2 (8.1%), and
vWF (7.9%). In addition, these CD34
+ uEPC expressed the stem/
progenitor markers AC133 (80.6%) and c-kit (95.3%).
Long-term Improvement of Blood Flow of Ischemic
Hindlimb by Human VPC-derived Vascular Cell
Transplantation
To examine the comparative effectiveness of transplanted
human VPC-derived vascular cells for vascular regeneration, we
set up six groups as follows (Figure 3);
1) EC+MC group (n=9): the mixture of 0.5610
6 human
VPC-derived EC and 0.5610
6 MC, with the total cell
number of 1610
6,
2) EC group (n=20): 0.5610
6 human VPC-derived EC,
3) MC group (n=18): 0.5610
6 human VPC-derived MC,
4) uEPC group (n=10): 1610
6 umbilical cord-derived CD34
+
cells,
5) pEPC group (n=16): 1610
6 peripheral mononuclear cells
(MNC)-derived EPC,
6) Control group (n=17): only 100 ml PBS.
To analyze subcutaneous hindlimb perfusion, laser Doppler
perfusion image (LDPI) analysis was performed (Figure 4a).
Throughout the 42 day follow-up period, significantly accelerated
limb perfusion improvement was observed in the VPC-derived
EC+MC-transplanted group, compared to the EPC and control
groups (Figure 4b, P,0.001 vs. control, pEPC, uEPC, and MC
groups, P =0.002 vs. EC group, repeated measures ANOVA
followed by Bonferoni’s multiple comparison test).
At day 14, blood flow of the mice transplanted with EPC (the
ratio of ischemic/non-ischemic blood flow: 0.90760.058 in pEPC
and 0.94260.075 in uEPC) (P=0.035 and 0.028, compared to the
control group), as well as MC (0.95760.056) (P=0.006) and EC
(0.90160.063) (P=0.032) showed significant increase, compared
to the control group (0.73060.042) (Figure 4b). In the EC+MC
group, the ratio of ischemic/non-ischemic blood flow markedly
elevated to 1.18760.083 (P,0.0001), compared to other groups.
Blood flow in the pEPC group, however, did not increase
thereafter and no significant difference in the blood flow between the
pEPC and control group was seen at days 28 and 42 (Figure 4b). In
the uEPC group, significant blood flow recovery was seen at day 42
(0.99060.054) (P=0.009), compared to the control group
(0.74960.039). The blood flow in the VPC-derived vascular cells-
transplanted groups progressively increased. At day 42, the calculated
perfusion ratio of ischemic to non-ischemic hindlimb significantly
elevated to 0.94360.057 for the MC (P=0.013), 1.03860.059 for
the EC (P=0.0002), and 1.23160.067 for the EC+MC group
(P,0.0001) compared to the control group (0.74960.039). Between
the cell mixture transplantation (EC+MC) group and the single cell
transplantation (EC or MC) groups, the blood flow of ischemic
hindlimbs was significantly different at day 42 (P,0.05).
Effective Contribution of Human VPC-derived Vascular
Cells for Vascular Regeneration
Fixed tissues harvested from ischemic hindlimbs at day 7 were
inspected by the fluorescence stereomicroscope (Leica, Wetzlar,
Human ES-Derived Vascular Cell
PLoS ONE | www.plosone.org 2 February 2008 | Volume 3 | Issue 2 | e1666Germany). Extended distribution of DiI-positive transplanted
cells was clearly seen in both VPC-derived EC+MC and pEPC-
transplanted hindlimbs (Figure 5a). We also detected some DiI-
positive vessel-like formation in the lung and spleen, but no
obvious tumor-like structures were seen (data not shown).
Ischemic hindlimbs at day 14 were sectioned and treated with
streptavidin conjugated dye to stain intravenously injected
biotinylated isolectin B4, followed by anti-human CD31 anti-
body, and scanned for the incorporation of transplanted cells into
circulating vessels. In the EC+MC group, we found that human
Figure 1. Characterization of transplanted human VPC-derived vascular cells. a) Flow cytometric analysis of cell surface markers on
expanded human VPC-derived VEGF-R2
+VE-cadherin
+ cells (=EC). b) Immunofluorescence image of CD31 (green) and aSMA (red) with nuclear
staining (blue) in expanded EC. Scale bar: 100 mm. c) Immunostaining of mural cell markers (brown) with hematoxyline counter-staining of expanded
VPC-derived VEGF-R2
+VE
2cadherin- cells (=MC). Scale bar: 100 mm. d, e) RT-PCR analysis of mural cell (d) and skeletal/cardiac specific (e) markers in
human VPC-derived vascular cells.
doi:10.1371/journal.pone.0001666.g001
Human ES-Derived Vascular Cell
PLoS ONE | www.plosone.org 3 February 2008 | Volume 3 | Issue 2 | e1666CD31 positive cells formed capillaries with host EC, which were
stained with isolectin B4 (Figure 5b: arrowhead). Furthermore,
some human CD31 positive cells solely formed capillary vessel
(Figure 5b: arrow), which might indicate de novo vessel
formation from human VPC-derived EC. We also detected
human CD31 positive cells in the pEPC and uEPC group;
however, many of these cells were located within the lumen of
host capillaries (Figure 5c, arrow).
Figure 2. Characterization of peripheral blood and umbilical cord-derived EPC (pEPC and uEPC, respectively) by flow cytometer. a)
Representative forward and side scatter profile of cultured pEPC. b-d) Flow cytometric analysis of ulex-lectin binding/acLDL uptake (b, c) and various
cell surface markers (d) in pEPC. e) Flow cytometric analysis of cell surface markers in uEPC.
doi:10.1371/journal.pone.0001666.g002
Human ES-Derived Vascular Cell
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derived MC to the recruitment of mural cells. We stained the
sections of ischemic hindlimbs at day 14 with anti-human SM1 and
aSMA antibodies. In EC+MC-transplanted mice, we found some
human SM1 and aSMA double positive cells, which were localized
within the aSMA positive host vessel wall (Figure 5d: arrow).
Quantification of Transplanted VPC-derived Vascular Cell-
induced Vascular Regeneration in Ischemic Hindlimb
The sections of ischemic hindlimbs of the EC+MC group at day
42 were stained with anti-human and mouse CD31 antibodies.
Mouse CD31 positive capillary density was significantly high in
the EC+MC group (1775.3654.2/mm
2), compared to other
groups (P,0.0001 vs. control group: 1318.6673.0/mm
2)
(Figure 6b). Human CD31 positive capillary density in mice
transplanted with human VPC-derived EC (EC (149.9612.3/
mm
2) and EC+MC (135.7613.7/mm
2) was significantly higher
than that in mice transplanted with EPC (95.768.5/mm
2 in the
pEPC and 115.2612.0/mm
2 in the uEPC group) (P,0.05).
Compatible with the result of blood flow measurement, mouse
and/or human CD31 positive capillary density markedly
increased in mice that received human VPC-derived EC+MC
(1856.8657.0/mm
2)( P,0.0001, compared to the control group
(1318.6673.0//mm
2)), and also to other groups. Among the single
cell transplantation groups, mouse and/or human CD31 positive
capillary density increased in the EC group (1601.4651.4/mm
2)
(P=0.0016) compared to the control group, but did not increase in
the MC (1471.8642.4/mm
2) or EPC groups (1403.5684.4/mm
2
in the pEPC and 1524.86108.2/mm
2 in the uEPC group).
To confirm the maturity of newly formed vessels, we performed
the immunostaining of the ischemic tissues with anti-aSMA
antibody, which could stain both human and mouse MC
(Figure 6c). We confirmed that aSMA positive capillary density
was significantly increased inthe human VPC-derived vascular cells-
transplanted groups (MC (1317.6645.4/mm
2), EC (1357.7627.3/
mm
2)a n dE C +MC (1554.9648.8/mm
2)) (P,0.0001), compared to
the control group (1021.3646.3/mm
2) (Figure 6d). Among the EPC
groups, aSMA positive capillary density was significantly increased
in the uEPC group (1185.7642.2/mm
2)( P,0.0076) compared to
the pEPC (1118.9636.8/mm
2) and control group. We further
investigated the extent of arteriogenesis in these groups using aSMA
immunostaining sections. Many aSMA positive arterioles with more
than 20 mm in diameter were detected in the EC+MC group, but
not in the control group (Figure 6c: arrowhead). The number of
aSMA positive arterioles significantly increased in the human VPC-
derived vascular cells-transplanted groups, especially in the EC+MC
group (the MC group:4.060.3/mm
2 and the EC group:3.760.2/
mm
2; P,0.001, compared to the control group: 2.060.2/mm
2,t h e
EC+MC group: 5.560.7/mm
2; P,0.0001, compared to all other
groups)(Figure6e).However,nosignificantdifferenceinthenumber
of aSMA positive arterioles was seen between the EPC (the pEPC
group:1.960.2/mm
2 and the uEPC group:2.060.2/mm
2)a n d
control groups.
Discussion
The present study demonstrated that the transplantation of
human VPC-derived vascular cells at the proper differentiation
Figure 3. Possible differentiation pathway of vascular cells from human ES cells via VPC.
doi:10.1371/journal.pone.0001666.g003
Human ES-Derived Vascular Cell
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tissue ischemia. After the expansion of human VPC-derived EC
and MC, when intra-arterially administered, these cells signifi-
cantly augmented neovascularization in an animal model of
experimentally-induced hindlimb ischemia, compared to human
peripheral blood and umbilical cord-derived EPC (pEPC and
uEPC). Furthermore, the combined transplantation of human
VPC-derived EC and MC could markedly induce vascular
regeneration, compared to the single fraction transplantation of
VPC-derived vascular cells (EC or MC). We also succeeded in
demonstrating that transplanted human VPC-derived vascular
cells were incorporated into the host circulation as both EC and
MC. These results indicate that the combined transplantation of
human VPC-derived EC and MC may have utility as a novel
strategy for vascular regenerative medicine.
In the present study we used human VPC-derived VEGFR2
+
VE-cadherin
+ cells for the expansion and transplantation of EC.
VEGFR2
+VE-cadherin
+ cells, obtained at day 10 of differenti-
ation, were also positive for CD34 and therefore considered to
be EC at the early differentiation stage (Figure 3) [9]. Even after
6 passages, 20,40% of these cells exhibited the expression of
VEGFR2, VE-cadherin, and CD34, which indicated that they
still retained the phenotype of EC at the early differentiated
stage. Compared to EPC, transplantation of these EC
significantly augmented ischemia-induced neovascularization. In
contrast, we found that ischemia-induced neovascularization was
not improved in mice receiving human aortic endothelial cells
[4]. Therefore, human VPC-derived EC at the early differen-
tiation stage might possess vascular regenerative capacity and
these EC can be a valuable source for promoting vascular
regeneration.
After expansion of human VPC-derived VEGFR2
+VE-cad-
herin
+ cells, about 70% of the expanded cells were aSMA positive.
However, these cells were negative for the mature mural cell
markers, including calponin, SM1, SM2, and h-caldesmon (data
not shown). In contrast, expanded VEGFR2
+ VE-cadherin
2 cells
obtained from human VPC under platelet derived growth factor
(PDGF)-BB stimulation were positive for aSMA, calponin, SM1,
and SM2, but negative for h-caldesmon. HAoSMC was positive
for all of the mature MC markers, including h-caldesmon. In
another series of our experiments, the mice receiving hAoSMC
transplantation exhibited no significant improvement of neovas-
cularization after the induction of ischemic hindlimbs (data not
shown). Because h-caldesmon and calponin were reported to be
expressed relatively late in SMC differentiation [10], human VPC-
derived MC might be at a rather early ‘‘immature’’ differentiation
Figure 4. Augmented vascular regeneration by intra-arterial transplantation of human VPC-derived vascular cells in a murine
hindlimb ischemia model. a) Serial LDPI analysis in hindlimb ischemia mice. At day 14, the blood flow of ischemic limbs in all cell transplanted
groups increased significantly compared to the control group (white arrowhead). After 42 days, significant blood flow recovery was observed in the
uEPC and human VPC-derived EC and/or MC-transplanted groups (red arrowhead), but not in pEPC. b) Quantitative analysis of hindlimb blood flow
by calculating the ischemic/normal limb perfusion ratios after the induction of hindlimb ischemia. *P,0.05 vs. control, {P,0.05 vs. pEPC, {{P,0.05
vs. uEPC, {P,0.05 vs. MC, 1P,0.05 vs. EC.
doi:10.1371/journal.pone.0001666.g004
Human ES-Derived Vascular Cell
PLoS ONE | www.plosone.org 6 February 2008 | Volume 3 | Issue 2 | e1666stage compared to hAoSMC, and thus, MC could be incorporated
into the site of neovascularization.
Recently, Ferreira et al. reported that transplantation of
human ES cells-derived EC into nude mice using Matrigel as
scaffold contributed for the formation of blood vessels [11].
However, they did not show the direct integration of transplanted
human ES cells-derived EC into host blood vessels. Judging from
the double staining using intravenously injected isolectin B4 and
anti-human specific CD31 antibody, we found that the
transplanted human VPC-derived EC incorporated into host
circulating vessels. These transplanted EC could solely form de
novo capillaries. In addition, by the double immunostaining of
human SM1 and aSMA, we confirmed that transplanted human
VPC-derived MC was also incorporated into host vessel walls.
Therefore, transplanted human VPC-derived EC and MC
structurally contributed to form new vessels in the process of
vascular regeneration.
Interaction between EC and MC is essential for vascular
development and maintenance of vascular stability [12,13].
Compared to only EC or MC-transplanted mice, the mice
transplanted with the combined transplantation of EC and MC
showed significant improvement after the induction of ischemic
hindlimb. At day 42, the blood flow in the EC+MC group was
significantly higher compared to only the EC or MC-transplanted
groups. Not only mouse and/or human CD31 but also aSMA
positive capillary density at day 42 significantly increased in the
EC+MC group. We also found that the density of aSMA positive
arterioles also significantly increased in the EC+MC group. These
results indicated that combined transplantation of human VPC-
derived EC and MC could synergistically contribute to vascular
Figure 5. Incorporated human VPC-derived vascular cells at the sites of vascular regeneration. a) Transplanted CM-DiI (red) labeled pEPC
or VPC-derived vascular cells in ischemic hindlimbs at day 7 were detected by the fluorescence stereomicroscope. Scale bar: 500 mm. b, c)
Immunostaining of frozen sections harvested from ischemic limb tissues at day 14. Fluorescence staining of GSL I-isolectin B4 (green) and human
CD31 (blue) with nuclear staining (red) in human VPC-derived EC+MC (b), pEPC, and uEPC (c) transplanted mice. Scale bar: 20 mm. d) Immunostaining
of aSMA (green)/human SM1 (blue) with nuclear staining (red) in human VPC-derived EC+MC-transplanted mice at day 14. Scale bar: 20 mm.
doi:10.1371/journal.pone.0001666.g005
Human ES-Derived Vascular Cell
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adequate MC coating.
VEGFR2 is one of the most specific markers involved in the
earliest stage of vascular endothelial and hematopoietic differen-
tiation [14]. Recent reports suggest that VEGFR2
+ mesodermal
progenitor cells also contribute muscle lineages including vascular
smooth, skeletal, and cardiac muscles [1,15]. This evidence
indicates the possibility that human VPC-derived MC, which
were expanded from VEGFR2
+TRA1
2VE-cadherin
2 cells, might
contain skeletal or cardiac muscle cells. However, 40-cycle RT-
PCR was confirmed negative for skeletal and cardiac specific
markers in expanded human VPC-derived MC. We cultured
VPC-derived MC on dishes coated with collagen type IV, which is
the major component of basement membrane. Previous reports
described that basement membrane played an essential role in
endothelial and smooth muscle cell differentiation [16]. Recently,
Xiao et al. demonstrated that pretreatment of mouse ES cells with
antibodies against collagen IV significantly inhibited smooth
muscle cell differentiation [17]. They also demonstrated PDGF
receptor-b signaling pathway plays a crucial role in ES cell-
derived smooth muscle cell differentiation using PDGF receptor-b
siRNA knockdown studies. Therefore, we suspected that, under
the presence of collagen type IV and PDGF-BB, our human
VPC-derived VE-cadherin negative cells could only differentiate
to MC.
Human VPC-derived EC+MC-transplanted KSN nude mice
showed considerable blood flow recovery, which led to more than
1.2 in the perfusion ratio of ischemic/non-ischemic limb. When
we transplanted human VPC-derived vascular cells to immuno-
suppressed C57BL/6 mice, the perfusion ratio elevated to nearly 1
(data not shown). Therefore, the tendency of the blood flow
recovery in C57BL/6 mice was consistent with the data of KSN
nude mice, the absolute value of blood flow ratio after hindlimb
ligation was different. Because both KSN nude and C57BL/6
mice received the same procedure for hindlimb ischemia, the
degree of perfusion recovery after induction of hindlimb ischemia
between these mice might reflect their difference in genetic
background for angiogenesis, as reported by Fukino et al [18].
They demonstrated that the VEGF and VEGFR1/2 expression in
response to ischemia was impaired in BALB/c mice, compared to
other mouse strains (i.e, C57BL/6J or C3H/He mice). These
results indicate that, because of the difference in genetic
background, spontaneous collateral formation might be acceler-
ated in our KSN nude mice compared to other strain mice.
In transplantation experiments, the number of mouse and/or
human CD31 and mouse CD31-positive capillary density in the
EC group was 1601.4651.4/mm
2 and 1470.1641.6/mm2,
respectively. This difference in capillary density (1601.4–
1470.1=131.3) was consistent with the number of human
CD31-positive capillary density (149.9612.3/mm
2). However,
Figure 6. Immunohistochemical analysis of human VPC-derived vascular cells-transplanted murine hindlimb tissues. a)
Representative fluorescent photographs of ischemic hindlimb stained for human (red) and mouse (green) CD31 at day 42. Overlapped-stained
capillaries are shown in arrowhead. Scale bar: 100 mm. b) Quantitative analysis of the endothelial cell marker positive capillary density in ischemic
hindlimbs at day 42. c) Representative aSMA immunostaining (brown) of ischemic hindlimbs at day 42. Scale bar. 100 mm. d) Quantitative analysis of
aSMA positive capillary density in ischemic hindlimbs at day 42. e) Quantitative analysis of aSMA positive arterioles (black arrowhead) at day 42.
*P,0.05 vs. control, {P,0.05 vs. pEPC, {{P,0.05 vs. uEPC, {P,0.05 vs. MC, 1P,0.05 vs. EC.
doi:10.1371/journal.pone.0001666.g006
Human ES-Derived Vascular Cell
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augmentation in mouse and/or human CD31 positive capillary
density without the increase of human CD31 positive capillary
density. One possible reason for this discrepancy is paracrine
effects of transplanted human VPC-derived vascular cells might
accelerate angiogenesis in ischemic tissues. We demonstrated that
cultured human VPC-derived vascular cells expressed several
angiogenic factors including VEGF, bFGF, HGF and PDGF-BB,
and the release of VEGF from human VPC-derived vascular cells
was significantly upregulated after transplantation (data not
shown) [4]. Therefore, in addition to the structural contribution
of transplanted human VPC-derived vascular cells into the host
vascular network, the paracrine effects of these cells might enhance
vascular regeneration in tissue ischemia.
Several reports described the contribution of pEPC or uEPC to
neovascularization in tissue ischemia [6,7]. However, it has not been
clearly demonstrated whether transplanted EPC augment neovas-
cularization through differentiation and proliferation into mature
EC or indirectly through paracrine stimulation of resident EC
proliferation. Rehamn et al. demonstrated that the majority of
pEPC, which were positive for acLDL and ulex-lectin, expressed
monocyte/macrophage markers, and only a minority cell fraction
expressed the specific endothelial or stem/progenitor markers [8].
They also demonstrated that pEPC did not proliferate, but released
several potent angiogenic growth factors. In this study,we confirmed
that a low percentage of cultured pEPC and uEPC expressed
endothelial makers. A considerable number of pEPC or uEPC were
localized inside the capillary lumen, not in the vessel wall. In
addition, we found that VEGF mRNA expression in transplanted
EPC was significantly higher compared with before transplantation
(data not shown). These results suggest that the majority of EPC
might have little ability to proliferate or differentiate to endothelial
linage, and their angiogenic effects could be attributed to angiogenic
factors secreted from transplanted EPC.
In conclusion, we have shown that human VPC-derived cells
could effectively differentiate and be expanded to EC and MC.
Combined transplantation of these ‘‘immature’’ VPC-derived
vascular cells, unlike ‘‘mature’’ somatic EC and MC, augmented
reparative neovascularization and contributed to make newly
formed vessels in the murine hindlimb ischemia model far more
effectively compared to EPC transplantation. Thus, human ES
cells-derived EC and MC can be used as the new promising cell
source for therapeutic vascular regeneration in patients with
tissue ischemia in order to realize a novel combined stem cell
therapy.
Materials and Methods
Differentiation of Human VPC-derived EC and MC
Maintenance of human ES cell line (HES3) was as previously
described [19]. To induce VPC, undifferentiated ES cells were
cultured on an OP9 feeder cell line as reported [3,4]. To obtain
human VPC-derived EC, VEGFR2
+TRA1
2VE-cadherin
+ cells
were sorted by fluorescence activated cell sorter (FACSAria;
Becton Dickinson, Bedford, MA) at day 10 of differentiation, and
cultured on type IV collagen-coated dishes (Becton Dickinson) in
the presence of 10% FCS and 50ng/ml VEGF (human VEGF165,
Peprotech Inc, Rocky Hill, NJ). After 6 passages of these cells, we
re-sorted VE-cadherin
+ cells for transplantation of human VPC-
derived EC. To expand human VPC-derived MC, sorted
VEGFR2
+TRA1
2VE-cadherin
2 cells derived from VPC at day
8 were re-cultured on type IV collagen-coated dishes with 1% FCS
and 20ng/ml human PDGF-BB (Peprotech Inc). We transplanted
these human VPC-derived MC after 6 passages.
Preparation of Human EPC
Peripheral MNC-derived EPC (pEPC) were obtained from
healthy volunteer, as previously described [6]. To confirm EPC
phenotype, cells were detached with cell dissociation buffer
(Invitrogen, Carlsbad, CA) and incubated with DiI-labeled acLDL
(Invitrogen) and FITC-labeled Ulex europaeus agglutinin I (ulex-
lectin) (Sigma-Aldrich, St. Louis, MO) for 1 hour. These cells were
analyzed by FACSAria to be confirmed as EPC [6,8].
Umbilical cord blood-derived CD34
+ EPC (uEPC) were isolated
from human umbilical cord blood, which were obtained from Cell
Bank, RIKEN BioResource Center (Tukuba, Japan). CD34
+ cells
were separated by a magnetic bead separation method using
autoMACS system with direct CD34
+ progenitor cell isolation kit
(Miltenyi Biotec GmbH, Gladbach, Germany) [7]. Protocols for
using human umbilical cord blood were approved by the Ethics
Committee of Kyoto University Graduate School of Medicine.
Characterization of VPC-derived Vascular Cells and EPC
To evaluate the surface marker phenotype of VPC-derived
vascular cells and EPC, these cells were detached by cell
dissociation buffer with or without collagenase (Wako Pure
Chemical Industries, Osaka, Japan) and labeled for 15 minutes
at 4uC with various fluorescence-conjugated monoclonal antibod-
ies (Table 1) [20]. Cells were washed and analyzed on FACSAria
flow cytometer with $30,000 events stored.
For the staining of cultured VPC-derived vascular cells on
dishes, cells were stained with anti-human CD31 (WM59) (Becton
Dickinson) antibody and several smooth muscle specific markers,
as shown in Table 2. Cultured hAoSMC (Cambrex, East
Rutherford, NJ) were used to obtain positive control staining.
For RT-PCR analysis, total RNA was prepared with RNeasy
Mini Kit (QIAGEN Inc., Valencia, CA), and RT-PCR was
performed by TaKaRa One Step RNA PCR Kit (TaKaRa Bio
Inc., Otsu, Japan). Total RNA from human heart and skeletal
muscle were purchased from Clontech (Mountain View, CA).
Primers are listed in Table 3 [21–23].
Hindlimb Ischemia Model and Cell Transplantation
After 8-week-old male KSN/Slc nude mice (Japan SLC,
Shizuoka, Japan) were anesthetized with pentobarbital (80mg/
kg, i.p.), the right femoral vein was ligated. To transplant vascular
cells intra-arterially, we injected these cells in 100 ml PBS into the
right femoral artery. Immediately after the cell injection, the right
femoral artery and vein were ligated and excised [24]. Animal
procedures were performed according to Kyoto University
standards for animal care.
Assessment of Transplanted Animals
The measurement of hindlimb blood flow was performed with a
LDPI analyzer (Moor Instruments, Devon, United Kingdom), as
previously described [24].
At arbitrary time points, biotin conjugated Griffonia simplici-
folia lectin (GSL) I-isolectin B4 (Vector Laboratories, Burlingame,
CA) in 100 ml PBS was injected into the portal vein 15 minutes
before sacrifice. Cryostat sections (10 mm thick) of the ischemic
lower legs were stained with anti-mouse/human CD31 (clone
WM59/Mec13.3) (Becton Dickinson) or anti-aSMA/human SM1
(clone 1A4/3F8) (DakoCytomation, Glostrup, Denmark/Yamasa
Co., Tokyo, Japan) antibodies. For biotinylated isolectin B4
staining to detect circulating vessels, sections were incubated with
streptoavidin conjugated Alexa Fluor dye (Invitrogen).
Capillary densities were examined by counting the number of
capillaries stained with anti-human and/or mouse CD31 or anti-
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Antibody Specificity Clone Supplier
Alpha smooth muscle actin (aSMA) Human & mouse 1A4 DakoCytomation Denmark A/S, Glostrup, Denmark Sigma-Aldrich, St. Louis, MO
Calponin Human CALP DakoCytomation Denmark A/S, Glostrup, Denmark
Smooth muscle myosin heavy chain 1 (SM1) Human 3FB Yamasa Co., Tokyo, Japan
Smooth muscle myosin heavy chain 2 (SM2) Human & mouse 1G12 Yamasa Co., Tokyo, Japan
doi:10.1371/journal.pone.0001666.t002
Table 3. Primers for reverse transcription-polymerase chain reaction
Gene Sequence Length (bp)
Calponin
1 Sense 59-CTTCATGGACGGCCTCAAAGA-39 713
Antisense 59-GTAGTTGTGTGCGTGGTGGTT-39
Smooth muscle myosin heavy chain 1 (SM1) and 2 (SM2)
1, 2 Sense 59-ATGAGGCCACGGAGAGCAACGA-39 178 (SM1)
Antisense 59-CCATTGAAGTCTGCGTCTCGA-39 217 (SM2)
h-caldesmon
1 Sense 59-AGACAAGGAAAGAGCTGAGGCA-39 395
Antisense 59-GCTGCTTGTTACGTTTCTGCTC-39
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
1 Sense 59-ACCACAGTCCATGCCATCAC-39 452
Antisense 59-TCCACCACCCTGTTGCTGTA-39
Myogenin
3 Sense 59-GTGGGCGTGTAAGGTGTGTA-39 141
Antisense 59-TGGTTGGGGTTGAGCAGGGT-39
MyoD
3 Sense 59-CCAAATGTAGCAGGTGTAAC-39 142
Antisense 59-AGAGATAAATACAGCCCCAG-39
Cardiac troponin T (cTnT)
4 Sense 59-GGCAGCGGAAGAGGATGCTGAA-39 150
Antisense 59-GAGGCACCAAGTTGGGCATGAACGA-39
Cardiac troponin I (cTnI)
4 Sense 59-CCCTGCACCAGCCCCAATCAGA-39 250
Antisense 59-CGAAGCCCAGCCCGGTCAACT-39
1Ref. 21.
2We used a single pair of PCR primers that cover the sequence specific to SM2, because these two isoforms are produced from a single gene by alternative splicing.
3Ref. 22.
4Ref. 23.
doi:10.1371/journal.pone.0001666.t003
Table 1. Fluorescence-conjugated monoclonal antibodies used for FACS analysis
Antibody Specificity Clone
Conjugated
fluorescence Supplier
VEGF-R2 Endothelial cells KM1998 Alexa Fluor 647 A generous gift of Prof. M. Shibuya, Tokyo University (Ref.20)
VE-cadherin Endothelial cells 55-7H1 FITC or PE Becton Dickinson, Bedford, MA
von Willebrand Factor (vWF) Endothelial cells 2F2-A9 Alexa Fluor 488 Becton Dickinson, Bedford, MA
CD31 (PECAM1) Endothelial cells or Monocytes WM59 Alexa Fluor 488 eBioscience, San Diego, CA
CD105 (Endoglin) Endothelial cells or Monocytes 266 Alexa Fluor 647 Becton Dickinson, Bedford, MA
CD11b (Mac1) Monocytes ICRF44 PE eBioscience, San Diego, CA
CD11c Monocytes B-ly6 FITC Becton Dickinson, Bedford, MA
CD14 Monocytes M5E2 APC Becton Dickinson, Bedford, MA
CD45 Panleukocytes HI30 PE Becton Dickinson, Bedford, MA
CD54 (ICAM-1) Panleukocytes 581 PE Becton Dickinson, Bedford, MA
AC133 Stem/Progenitor cells AC133 PE Miltenyi Biotec GmbH, Bergisch Gladbach, Germany
c-kit Stem/Progenitor cells YB5.B8 APC Becton Dickinson, Bedford, MA
CD34 Stem/Progenitor cells 581 FITC Becton Dickinson, Bedford, MA
doi:10.1371/journal.pone.0001666.t001
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fields on two different sections (approximately 3mm apart) from
each mouse were photographed and analyzed by NIH image as
previously described [24].
Statistical Analysis
Results are presented as means6S.E.M. The serial changes of
the hindlimb blood flow were assessed by repeated measures
ANOVA, followed by Bonferoni’s multiple comparison test.
Comparisons among groups were tested by one-way ANOVA
followed by Bonferoni’s multiple comparison test. A P value ,0.05
was considered significant.
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